The stimulant drug Vyvnase improves the symptoms of attention deficit hyperactivity disorder (ADHD) within the first week of treatment, research has suggested.
“We saw a 50% improvement in symptoms,” Dr Ann Childress told the American Psychiatric Association’s annual meeting in New Orleans.
“Vyvnase improved symptoms of inattention, hyperactivity and impulsivity compared to placebo.”
The randomised trial involved 309 volunteers between the ages of 13 and 17, each with moderate ADHD symptoms. The participants were split into Vyvnase and placebo groups.
Childress said differences in the test group became visible within the first week of treatment and remained constant throughout the investigation. Nearly twice as many Vyvnase subjects were rated as very much or much improved by the time the trial finished.
The drug is currently used in the US to treat adults and children between the ages of 6 and 12.
Maker Shire recently applied for FDA approval to market the drug to adolescents.
Copyright Press Association 2010